Vibozilimod

Overview

Vibozilimod (SCD-044) is an oral S1P1/EDG1 receptor-selective agonist with an EC 50 of <1 nM. Vibozilimod promotes S1P1/EDG1 receptor internalization, inhibits lymphocyte migration, induces lymphopenia and reduces lymphocyte counts. Vibozilimod is used for the research of inflammatory diseases such as psoriasis and atopic dermatitis.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Allergy | Products > Disease Areas > Psoriasis | Products > Disease Areas > Atopic Dermatitis | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > LPL Receptor

Product Information

• Catalog No.: HY-132847
• CAS No.: 1403232-33-6
• Molecular Formula: C29H36ClN3O5
• Molecular Weight: 542.07
• Purity: 99.52%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source